Demographic and experimental data for sarcoidosis and HDLS patients and control subjects
| . | . | . | . | . | . | CD16-positive monocytes . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases and controls . | Gender . | Age, y . | Classical monocytes, cells per μL . | Classical monocytes, % . | Total classical, intermediate (CD14), and nonclassical (CD14), cells per μL . | CD14++ intermediate monocytes, cells per μL . | CD14++ intermediate monocytes, % . | CD14+ nonclassical monocytes, cells per μL . | CD14+ nonclassical monocytes, % . | slan− intermediate monocytes, cells per μL . | slan− intermediate monocytes, % . | slan+ nonclassical monocytes, cells per μL . | slan+ nonclassical monocytes, % . |
| Sarcoidosis radiologic stage (proband ID) | |||||||||||||
| III (2062) | M | 66 | 494.2 | 75.3 | 655.9 | 64.0 | 9.8 | 97.7 | 14.9 | 140.4 | 21.4 | 45.6 | 7.0 |
| II (2061) | M | 63 | 1220.0 | 84.9 | 1437.6 | 46.9 | 3.3 | 170.8 | 11.9 | 164.3 | 11.4 | 63.8 | 4.4 |
| I (2065) | M | 53 | 338.7 | 87.5 | 387.0 | 23.2 | 6.0 | 25.2 | 6.5 | 36.6 | 9.4 | 24.4 | 6.3 |
| I (2073) | M | 45 | 388.2 | 84.6 | 458.7 | 33.6 | 7.3 | 36.9 | 8.0 | 46.2 | 10.1 | 25.8 | 5.6 |
| I (2074) | M | 28 | 427.6 | 65.6 | 652.3 | 101.6 | 15.6 | 123.2 | 18.9 | 164.7 | 25.3 | 61.0 | 9.4 |
| II (2078) | M | 35 | 374.7 | 83.9 | 446.4 | 27.1 | 6.1 | 44.6 | 10.0 | 58.5 | 13.1 | 13.1 | 2.9 |
| II (2131) | M | 53 | 351.6 | 62.8 | 560.1 | 96.0 | 17.1 | 112.5 | 20.1 | 128.5 | 22.9 | 48.2 | 8.6 |
| Mean | 49 | 513.6 | 77.8 | 656.9 | 56.0 | 9.3 | 87.3 | 12.9 | 95.7 | 16.2 | 36.8 | 6.3 | |
| SD | 13.96 | 315.9 | 10.1 | 359.5 | 32.2 | 5.2 | 53.6 | 5.3 | 55.0 | 6.7 | 18.8 | 2.2 | |
| P = .032 | P = .040 | P = .015 | P = .025 | ||||||||||
| II (2079) | F | 31 | 328.5 | 82.4 | 398.9 | 31.8 | 8.0 | 38.5 | 9.7 | 60.9 | 15.3 | 16.7 | 4.2 |
| 0* (2080) | F | 36 | 349.0 | 80.7 | 432.4 | 35.4 | 8.2 | 48.0 | 11.1 | 65.4 | 15.1 | 17.9 | 4.1 |
| I (2088) | F | 62 | 351.2 | 85.9 | 408.9 | 19.6 | 4.8 | 38.1 | 9.3 | 51.0 | 12.5 | 6.5 | 1.6 |
| II (2094) | F | 50 | 283.7 | 79.1 | 358.6 | 23.3 | 6.5 | 51.6 | 14.4 | 44.4 | 12.4 | 28.6 | 8.0 |
| II (2102) | F | 71 | 628.7 | 95.9 | 655.7 | 16.8 | 2.6 | 10.2 | 1.6 | 24.9 | 3.8 | 2.6 | 0.4 |
| I (2112) | F | 34 | 222.8 | 89.2 | 249.7 | 11.0 | 4.4 | 15.9 | 6.4 | 15.0 | 6.0 | 11.8 | 4.7 |
| I (2146) | F | 58 | 248.6 | 67.8 | 366.4 | 42.0 | 11.5 | 75.8 | 20.7 | 100.6 | 27.5 | 23.5 | 6.4 |
| Mean | 48.9 | 344.7 | 83.0 | 410.1 | 25.7 | 6.6 | 39.7 | 10.4 | 51.7 | 13.2 | 15.4 | 4.2 | |
| SD | 15.56 | 134.7 | 8.8 | 123.3 | 11.1 | 3.0 | 22.2 | 6.0 | 28.2 | 7.7 | 9.2 | 2.6 | |
| HDLS mutation (proband ID) | |||||||||||||
| 2342C>T, A781V (667) | F | 22 | 433.0 | 98.4 | 439.8 | 3.0 | 0.7 | 3.7 | 0.8 | 4.2 | 1.0 | 2.6 | 0.6 |
| 1745T>C, L582P (692) | M | 47 | 295.0 | 90.6 | 325.5 | 14.0 | 4.3 | 18.0 | 5.5 | 23.0 | 7.1 | 7.5 | 2.3 |
| 1897G>A, E633K (745) | F | 47 | 625.0 | 91.6 | 682.3 | 39.0 | 5.7 | 24.0 | 3.5 | 50.0 | 7.3 | 7.3 | 1.1 |
| 2512G>C, V838L (766) | M | 58 | 284.0 | 91.3 | 309.4 | 13.0 | 4.2 | 14.0 | 4.5 | 21.0 | 6.8 | 4.4 | 1.4 |
| Mean | 43.5 | 409.3 | 93.0 | 439.3 | 17.3 | 3.7 | 14.9 | 3.6 | 24.6 | 5.6 | 5.5 | 1.4 | |
| SD | 15.2 | 159.0 | 3.6 | 172.1 | 15.3 | 2.1 | 8.5 | 2.0 | 18.9 | 3.0 | 2.4 | 0.7 | |
| P = .011 | P = .005 | P = .005 | P = .002 | P = .002 | |||||||||
| Controls, n | |||||||||||||
| 10 | M | ||||||||||||
| Mean | 38.80 | 392.8 | 85.2 | 465.0 | 24.0 | 5.0 | 48.1 | 9.8 | 41.7 | 8.5 | 36.8 | 7.5 | |
| SD | 12.81 | 84.5 | 4.8 | 116.1 | 11.2 | 1.6 | 27.5 | 3.7 | 24.1 | 3.2 | 23.0 | 3.4 | |
| 10 | F | ||||||||||||
| Mean | 48.1 | 433.6 | 85.5 | 504.7 | 21.8 | 4.5 | 49.3 | 10.0 | 46.2 | 9.6 | 26.6 | 5.2 | |
| SD | 11.1 | 93.9 | 5.9 | 91.8 | 7.4 | 1.8 | 19.9 | 4.4 | 18.2 | 4.7 | 16.3 | 3.0 | |
| 20 | M + F | ||||||||||||
| Mean | 43.5 | 413.2 | 85.3 | 484.8 | 22.9 | 4.7 | 48.7 | 9.9 | 44.0 | 9.1 | 31.7 | 6.4 | |
| SD | 12.6 | 89.4 | 5.3 | 103.9 | 9.3 | 1.7 | 23.4 | 4.0 | 20.9 | 4.0 | 20.1 | 3.3 | |
| . | . | . | . | . | . | CD16-positive monocytes . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases and controls . | Gender . | Age, y . | Classical monocytes, cells per μL . | Classical monocytes, % . | Total classical, intermediate (CD14), and nonclassical (CD14), cells per μL . | CD14++ intermediate monocytes, cells per μL . | CD14++ intermediate monocytes, % . | CD14+ nonclassical monocytes, cells per μL . | CD14+ nonclassical monocytes, % . | slan− intermediate monocytes, cells per μL . | slan− intermediate monocytes, % . | slan+ nonclassical monocytes, cells per μL . | slan+ nonclassical monocytes, % . |
| Sarcoidosis radiologic stage (proband ID) | |||||||||||||
| III (2062) | M | 66 | 494.2 | 75.3 | 655.9 | 64.0 | 9.8 | 97.7 | 14.9 | 140.4 | 21.4 | 45.6 | 7.0 |
| II (2061) | M | 63 | 1220.0 | 84.9 | 1437.6 | 46.9 | 3.3 | 170.8 | 11.9 | 164.3 | 11.4 | 63.8 | 4.4 |
| I (2065) | M | 53 | 338.7 | 87.5 | 387.0 | 23.2 | 6.0 | 25.2 | 6.5 | 36.6 | 9.4 | 24.4 | 6.3 |
| I (2073) | M | 45 | 388.2 | 84.6 | 458.7 | 33.6 | 7.3 | 36.9 | 8.0 | 46.2 | 10.1 | 25.8 | 5.6 |
| I (2074) | M | 28 | 427.6 | 65.6 | 652.3 | 101.6 | 15.6 | 123.2 | 18.9 | 164.7 | 25.3 | 61.0 | 9.4 |
| II (2078) | M | 35 | 374.7 | 83.9 | 446.4 | 27.1 | 6.1 | 44.6 | 10.0 | 58.5 | 13.1 | 13.1 | 2.9 |
| II (2131) | M | 53 | 351.6 | 62.8 | 560.1 | 96.0 | 17.1 | 112.5 | 20.1 | 128.5 | 22.9 | 48.2 | 8.6 |
| Mean | 49 | 513.6 | 77.8 | 656.9 | 56.0 | 9.3 | 87.3 | 12.9 | 95.7 | 16.2 | 36.8 | 6.3 | |
| SD | 13.96 | 315.9 | 10.1 | 359.5 | 32.2 | 5.2 | 53.6 | 5.3 | 55.0 | 6.7 | 18.8 | 2.2 | |
| P = .032 | P = .040 | P = .015 | P = .025 | ||||||||||
| II (2079) | F | 31 | 328.5 | 82.4 | 398.9 | 31.8 | 8.0 | 38.5 | 9.7 | 60.9 | 15.3 | 16.7 | 4.2 |
| 0* (2080) | F | 36 | 349.0 | 80.7 | 432.4 | 35.4 | 8.2 | 48.0 | 11.1 | 65.4 | 15.1 | 17.9 | 4.1 |
| I (2088) | F | 62 | 351.2 | 85.9 | 408.9 | 19.6 | 4.8 | 38.1 | 9.3 | 51.0 | 12.5 | 6.5 | 1.6 |
| II (2094) | F | 50 | 283.7 | 79.1 | 358.6 | 23.3 | 6.5 | 51.6 | 14.4 | 44.4 | 12.4 | 28.6 | 8.0 |
| II (2102) | F | 71 | 628.7 | 95.9 | 655.7 | 16.8 | 2.6 | 10.2 | 1.6 | 24.9 | 3.8 | 2.6 | 0.4 |
| I (2112) | F | 34 | 222.8 | 89.2 | 249.7 | 11.0 | 4.4 | 15.9 | 6.4 | 15.0 | 6.0 | 11.8 | 4.7 |
| I (2146) | F | 58 | 248.6 | 67.8 | 366.4 | 42.0 | 11.5 | 75.8 | 20.7 | 100.6 | 27.5 | 23.5 | 6.4 |
| Mean | 48.9 | 344.7 | 83.0 | 410.1 | 25.7 | 6.6 | 39.7 | 10.4 | 51.7 | 13.2 | 15.4 | 4.2 | |
| SD | 15.56 | 134.7 | 8.8 | 123.3 | 11.1 | 3.0 | 22.2 | 6.0 | 28.2 | 7.7 | 9.2 | 2.6 | |
| HDLS mutation (proband ID) | |||||||||||||
| 2342C>T, A781V (667) | F | 22 | 433.0 | 98.4 | 439.8 | 3.0 | 0.7 | 3.7 | 0.8 | 4.2 | 1.0 | 2.6 | 0.6 |
| 1745T>C, L582P (692) | M | 47 | 295.0 | 90.6 | 325.5 | 14.0 | 4.3 | 18.0 | 5.5 | 23.0 | 7.1 | 7.5 | 2.3 |
| 1897G>A, E633K (745) | F | 47 | 625.0 | 91.6 | 682.3 | 39.0 | 5.7 | 24.0 | 3.5 | 50.0 | 7.3 | 7.3 | 1.1 |
| 2512G>C, V838L (766) | M | 58 | 284.0 | 91.3 | 309.4 | 13.0 | 4.2 | 14.0 | 4.5 | 21.0 | 6.8 | 4.4 | 1.4 |
| Mean | 43.5 | 409.3 | 93.0 | 439.3 | 17.3 | 3.7 | 14.9 | 3.6 | 24.6 | 5.6 | 5.5 | 1.4 | |
| SD | 15.2 | 159.0 | 3.6 | 172.1 | 15.3 | 2.1 | 8.5 | 2.0 | 18.9 | 3.0 | 2.4 | 0.7 | |
| P = .011 | P = .005 | P = .005 | P = .002 | P = .002 | |||||||||
| Controls, n | |||||||||||||
| 10 | M | ||||||||||||
| Mean | 38.80 | 392.8 | 85.2 | 465.0 | 24.0 | 5.0 | 48.1 | 9.8 | 41.7 | 8.5 | 36.8 | 7.5 | |
| SD | 12.81 | 84.5 | 4.8 | 116.1 | 11.2 | 1.6 | 27.5 | 3.7 | 24.1 | 3.2 | 23.0 | 3.4 | |
| 10 | F | ||||||||||||
| Mean | 48.1 | 433.6 | 85.5 | 504.7 | 21.8 | 4.5 | 49.3 | 10.0 | 46.2 | 9.6 | 26.6 | 5.2 | |
| SD | 11.1 | 93.9 | 5.9 | 91.8 | 7.4 | 1.8 | 19.9 | 4.4 | 18.2 | 4.7 | 16.3 | 3.0 | |
| 20 | M + F | ||||||||||||
| Mean | 43.5 | 413.2 | 85.3 | 484.8 | 22.9 | 4.7 | 48.7 | 9.9 | 44.0 | 9.1 | 31.7 | 6.4 | |
| SD | 12.6 | 89.4 | 5.3 | 103.9 | 9.3 | 1.7 | 23.4 | 4.0 | 20.9 | 4.0 | 20.1 | 3.3 | |
Histology in all sarcoidosis patients showed noncaseating epitheloid granulomas. P < .05 compared to gender-matched controls (Mann-Whitney U test).
F, female; ID, identification number; M, male; SD, standard deviation.
Granulomas in bronchial wall.